Table 4. Estimates of Aspirin's Role in Hemorrhagic Stroke and Intracranial Hemorrhage*

Trial

Aspirin
Events/Patients (%)

Control
Events/Patients (%)

Odds Ratio
(95% CI)

Duration of Therapy

Annual Approximate Control Group Risk

Approximate Excess Bleeding Events per 1,000 Patients Treated per Year

BMD5

13/3,429
(0.38)

6/1,710
(0.35)

1.08
(0.41 to 2.85)

5.8 years

0.06%

0.05

PHS4

23/11,037
(0.21)

12/11,034
(0.11)

1.92
(0.95 to 3.86)

5 years

0.02%

0.2

TPT7

3/1,268
(0.24)

2/1,272
(0.16)

1.51
(0.25 to 9.03)

6.8 years

0.02%

0.12

HOT8

14/9,399
(0.15)

15/9,391
(0.16)

0.93
(0.45 to 1.93)

3.8 years

0.04%

0.03 fewer events

PPP9

2/2,226
(0.08)

3/2,269
(0.13)

0.67
(NR)

3.6 years

0.04%

0.12 fewer events

*BMD indicates British Male Doctors' Trial; HOT, Hypertension Optimal Treatment Trial; NR, not reported; PHS, Physicians' Health Study; PPP, Primary Prevention Project; TPT, Thrombosis Prevention Trial.

Return to Document